Introduction
============

Tumor heterogeneity \[[@B1]-[@B4]\] is an old concept but its impact on the cancerogenesis process is poorly understood. Breast cancer is a noteworthy model for its frequency, and for the diversity of its phenotypes and of its evolution. This study examines the influence of the heterogeneity of tumor proliferation on disease-free survival of patients with a breast carcinoma.

Material and methods
====================

Histological slides
-------------------

The study involved a series of 368 patients from the François Baclesse Cancer Centre (Caen) treated for a breast carcinoma between 1991 and 1995, whitout neoadjuvant therapy and with a follow-up of more than 15 years. The table [1](#T1){ref-type="table"} contains the description of the series.

###### 

Univariate Analysis of Disease Free Survival -- 368 Eligible Patients. In grey: Follow up (2011)

  Variable                                                  No. of patients         *P*value       
  --------------------------------------------------------- ----------------------- -------------- ----------
  Age                                                                                              
                                                            Mean = 58.7 yr                         0.400
  Menopauses                                                                                       
                                                            Yes                     237 (65%)      
                                                            No                      124 (34%)      
  Localization                                                                                     
                                                            Right breast            176 (47.8%)    
                                                            Left breast             187 (50.8%)    
                                                            Synchronous bilateral   5 (01.4%)      
  Tumor size                                                                                       
                                                            Mean = 25 mm                           0.010
  Surgery                                                                                          
                                                            Tumorectomy             212 (57.6%)    
                                                            Mastectomy              141 (38.3%)    
                                                            Biopsy                  15 (04.1%)     
  Excision quality                                                                                 
                                                            Satisfying              202 (57.2%)    
                                                            Unsatisfying            47 (13.3%)     
                                                            Unspecified             104 (29.5%)    
  Histological type                                                                                
                                                            ICC                     297 (80.71%)   
                                                            ILC                     37 (10.05%)    
  SBR grade                                                                                        
                                                            Grade 1                 50 (14%)       
                                                            Grade 2                 180 (49%)      0.002
                                                            Grade 3                 137 (37%)      
  Mitotic index (/1.7mm²)                                                                          
                                                            Mean = 10 mitosis                      \<0.0001
  Tumor vascular emboli                                                                            
                                                            Yes                     293 (79.6%)    
                                                            No                      75 (20.4%)     
  Lymph node metastasis                                                                            
                                                            Yes                     153 (44%)      \<0.0001
                                                            No                      195 (56%)      
  Hormone receptor status (at least 1)                                                             
                                                            Yes                     265 (73%)      0.030
                                                            No                      98 (27%)       
                                                                                                   
  Visceral or lymph node (other than axillary) metastasis                                          
                                                            Yes                     136 (37%)      
                                                            No                      232 (63%)      
  Local recurrence                                                                                 
                                                            Yes                     66 (18%)       
                                                            No                      302 (82%)      
  Oncological event (Metastasis and/or local recurrence)                                           
                                                            Yes                     157 (42.5%)    
                                                            No                      211 (57.5%)    
  Death                                                                                            
                                                            Yes                     90 (24.46%)    
                                                            No                      278 (75.54%)   

Histological sections, representative of each tumor, have been stained with the anti-phosphohistone-H3 antibody (PHH3: Ser10, MILLIPORE®, dilution 1/600) \[[@B5],[@B6]\]. With this specific immuno-stain, cells presenting mitosis figures are more easily identifiable (Figure [1](#F1){ref-type="fig"}).

![**dyes used to stain the histological sections.a**: histological slide stained with HES; **b**: histological slide of the same case immunohistochemically stained with PHH3 \[[@B6]-[@B8]\] (anti-phosphohistone-H3 antibody); **c**: thanks to this specific immunohistochemical, identification of cells with mitosis figures, from prophase to telophase, is improved.](1746-1596-8-S1-S43-1){#F1}

Acquisition
-----------

Histological slides have been scanned with a high resolution slide scanner to obtain virtual slides with a final resolution of 0.5 µm (ScanScope® CS from Aperio Technologies (20x NA 0.7 objective). The true color images obtained (color RGB 24 bits) have been saved in the tiled pyramidal TIFF file format.

Region of interest (ROI)
------------------------

Before the automatic image analysis, the user can discard "normal" tissue surrounding the tumor by drawing a region of interest on the high resolution virtual slide with the Aperio ImageScope® software.

Image processing
----------------

The image processing was performed in two steps on a personal computer with a 1.6 GHz Pentium IV processor and a 1 GB of random access memory (RAM). The first step being a sub-sampling of virtual slide done with a specific algorithm \'Daubechies\' second moment orthogonal wavelet decimation developed in C++ language which creates a low resolution image of the virtual slide (divided by 8: from 0.5µm to 4µm/pixels). In a second step, the low resolution image is automatically processed thanks to chaining operators of image analysis toolbox software (Aphelion, ADCIS).

In addition to estimating the frequency of mitotic figures, the program detects "hot spots" and measures 9 features representing the tumor heterogeneity, including the Haralick texture features and Fisher's index. The zones of influence of each stained nuclei have been determined using Voronoï's pavement principle. When nuclei are close, the size of pavements is small, highlighting the "hot spots".

Feature selection
-----------------

A principal component analysis has been done in order to select the most relevant features.

Statistic analysis
------------------

These features have been statistically analyzed, combined with classic clinic-pathological prognostic factors (age, tumor size, grading, mitotic index, vascular emboli and metastatic lymph nodes).

Results
=======

Principal component analysis
----------------------------

Thanks to the principal component analysis (PCA) 4 features representing tumor heterogeneity have been chosen then combined into three new features: CP1, CP2 and CP3, corresponding to the three principal directions of the PCA.

The four selected features are:

\- 2 Haralick's texture indexes (correlation and energy);

\- Fisher's index;

\- variance of the size of Voronoï pavements.

The variance of the size of Voronoï pavement (named Voronoï) and the Fisher's index are regional features whereas the Haralick's texture indexes are local features. Indeed, Voronoï and Fisher features are "cutting" the tissue into pieces and analyzing each of them compared to the others, whereas Haralick is dealing with relations between neighbor pixels, each pixel representing a cell at this resolution.

Prognostic study
----------------

In the analysis of prognostic factors, disease free survival was used as the end point.

### Univariate statistical analysis (DFS)

Univariate analysis of disease free survival was performed with the features of age, tumor location, initial tumor size, pathologic lymph node status (N), histological type, SBR grade, mitotic index, vascular emboli, metastatic lymph nodes and hormone receptor status. The results are shown in Table [1](#T1){ref-type="table"} for usual features, in Table [2](#T2){ref-type="table"} for heterogeneity features.

###### 

Results of the univariate analysis

  Variables                        P value
  -------------------------------- ---------
  Voronoï                          0.040
                                   
  Normalized variance of density   0.170
                                   
  Energy (Haralick)                0.090
                                   
  CP1                              0.500
                                   
  CP2                              0.016
                                   
  CP3                              0.670

The CP2 feature correlated highly with disease free survival, whereas the variance of the Voronoï pavements was borderline significant.

### Multivariate statistical analysis (Cox)

The above features that correlated with disease free survival in univariate analysis were combined with clinic-pathologic factors and included in the multivariate analysis. Cox's regression analysis highlighted 3 independent prognostic factors: tumor heterogeneity feature CP2 (RR = 1.46; p = 0.03), mitotic index (RR = 1.71; p = 0.004) and lymph node metastasis (RR = 2.20, p \< 0.0001) correlated highly with disease free survival.

The construction of this model has individualized 3 groups of patients: 0 factor, 1 or 2 factors and 3 poor prognostic factors (mitotic index \> 10, lymph node metastasis in the axillary dissection, upper tercile of CP2; p \< 0.0001).

Disease free survival according to this model is shown in Figure [2](#F2){ref-type="fig"}.

![**Model build using the results of the multivariate analysis.** Multivariate analysis highlighted 3 independent prognostic factors: tumor heterogeneity (CP2), mitotic index, lymph node metastasis. The construction of this model has individualized 3 groups of patients: 0 factor, 1 or 2 factors and 3 poor prognostic factors (mitotic index \> 10, lymph node metastasis in the axillary dissection, upper tercile of CP2; p \< 0.0001).](1746-1596-8-S1-S43-2){#F2}

Discussion and conclusion
=========================

To characterize tumor heterogeneity in the presented series of breast cancer, 9 features were computed. 4 nonredundant of them have been selected by principal component analysis (PCA).

PCA was also used to create 3 new composite features: CP1, CP2 and CP3, corresponding to the 3 principal directions of the PCA.

The univariate analysis made for each feature from image analysis has first highlighted that only the combination CP2 and Voronoï's feature had a prognostic value. It has to be noted that a high value of heterogeneity index is associated with a poor prognosis.

In multivariate analysis, CP2 was found to be an independent prognostic feature just like the mitotic index and the lymph node status. The lymph node status is a well-known clinical factor; the two other features are intrinsic factors of tumor growth, at cellular level for mitotic index and at the tissue level for heterogeneity.

Surprisingly, age, tumor size, Scarff and Bloom Grade and hormone receptor status are of secondary importance compared to these 3 features.

This result encourages to confront the heterogeneity feature CP2 to clinic information, such as recent or late oncologic event or the nature locoregional or distant visceral of the recurrence, and to the absence of lymph node metastasis.
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